Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, 27 November 2023 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that ExpreS2ion CEO Bent Frandsen participated in a Finwire interview, CFO Keith Alexander participated in the Økonomisk Ugebrev Life Science Investor Conference on 22 November, and Analysguiden has published a research report on ExpreS2ion in November.
An interview with CEO Bent Frandsen, hosted by Finwire, and a presentation by CFO Keith Alexander at the Økonomisk Ugebrev Life Science Investor Conference on 22 November 2023, can both be found on the presentations page (https://investor.expres2ionbio.com/presentations/) of the ExpreS[2]ion investor website (https://investor.expres2ionbio.com/).
The Analysguiden report dives deeper into the Company's strategic changes and comments on a potential dividend payment related to milestones from the ABNCoV2 COVID-19 vaccine, the "post-covid" strategy, especially as it relates to the ES2B-C001 breast cancer vaccine asset, updates to the malaria programs and valuation, including an analysis of ExpreS[2]ion's holding in AdaptVac ApS. Analysguiden revised its price target to SEK 2.20 per share. The research report is available on the Analyst Reports (https://investor.expres2ionbio.com/analyst-reports/) page of ExpreS[2]ion's investor website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB